Aggrecan Antibody, C-terminal Neoepitope NITEGE

Product Description

Aggrecan Antibody, C-terminal Neoepitope NITEGE
Catalog number: B2026951
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 0.1 mg/mL
Supplied as: Solution
Storage: −20°C
Keywords: ACAN, AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK, SSOAOD, Aggrecan core protein, Cartilage-specific proteoglycan core protein, Chondroitin sulfate proteoglycan 1, Chondroitin sulfate proteoglycan core protein 1, CSPCP, large aggregating proteoglycan, AGC1SEDK, CSPG1aggrecan 1, MSK16AGCAN

References:
“1. Fosang AJ, Last K, Gardiner P, et al. (2000). Septic arthritis, but not zymosan-induced arthritis, causes the generation of NITEGE and VDIPEN neoepitopes in murine articular cartilage. Arthritis & Rheumatism, 43(12), 2636-2644.
2. Little CB, Flannery CR, Hughes CE, et al. (1999). Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in rat articular cartilage. Biochemical Journal, 344(1), 61-68.
3. van Meurs JB, van Lent PL, Stoop R, et al. (1999). Cleavage of aggrecan at the Asn341-Phe342 site coincides with the onset of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin-1 in the progression from reversible to irreversible cartilage damage. Arthritis & Rheumatism, 42(10), 2074-2084.
4. Fosang AJ, Last K, Knauper V, et al. (1996). Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Letters, 380(1-2), 17-20.
5. Lark MW, Bayne EK, Flanagan J, et al. (1997). Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. Journal of Clinical Investigation, 100(1), 93-106.
6. Hughes CE, Little CB, Buttner FH, et al. (1998). Differential expression of aggrecanase and matrix metalloproteinase neoepitopes in joint fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis & Rheumatism, 41(1), 85-91.
7. Caterson B, Flannery CR, Hughes CE, et al. (2000). Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biology, 19(4), 333-344.
8. Pratta MA, Yao W, Decicco CP, et al. (2003). Aggrecan-mediated cartilage degradation in an in vitro model of articular cartilage catabolism. Journal of Biological Chemistry, 278(46), 45539-45545.
9. Stanton H, Rogerson FM, East CJ, et al. (2005). ADAMTS5 is the primary aggrecanase in murine cartilage. Nature, 434(7033), 648-652.
10. Glasson SS, Askew R, Sheppard B, et al. (2005). Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature, 434(7033), 644-648.”
Aggrecan Antibody, C-terminal neoepitope NITEGE

Products Related to Aggrecan Antibody, C-terminal Neoepitope NITEGE can be found at Antibodies